BCG's Ben Aylor demonstrates why companies must regularly adjust to changes in the global trade environment to counteract economic uncertainty.

Ben Aylor is a core member of Boston Consulting Group’s Health Care and Operations practice areas. He is BCG's global topic leader on network strategy for pharmaceutical manufacturing and has extensive experience with both strategy and operations projects in the pharmaceuticals industry, including biopharma network designs, operations transformations, make/buy analyses, and sourcing strategies.

Ben’s current focus is on helping clients build their capabilities in new areas—such as digital supply chain—and meet the challenges of major change efforts including post-merger integrations and broad transformations. Ben has led both overall corporate PMI programs and the manufacturing aspects of PMIs.

Before joining the firm, Ben worked at Arthur Andersen Business Consulting.

AREAS OF EXPERTISE

EDUCATION

  • MBA, MIT, Sloan School of Management
  • BS, University of Virginia

Publications and Videos

Biopharma Carve-Outs Are Tricky - rectangle

Biopharma Carve-Outs Are Tricky. Here’s How to Get Them Right.

Through carve-outs, companies can create value, streamline portfolios, and reduce complexity. But the ultimate success of a deal hinges on focused, proactive execution.
Real-World Supply Chain Resilience

Real-World Supply Chain Resilience

Efficiency in supply chain operations shouldn’t come at the expense of flexibility. Here’s how leading companies achieve both.
" "

Dispel These Myths to Maximize Value in Small and Midsize Biopharma M&A

Acquirers need to plan their integrations carefully and act quickly, but too often they delay decision making and destroy value.
How President-Elect Biden Will Approach Global Trade

How President-Elect Biden Will Approach Global Trade

The new administration will fight to advance and protect US economic interests—but America will no longer go it alone.
" "

Planning for the Unpredictable in Health Care Supply Chains

As the current crisis demonstrates, biopharma and medtech companies need to safeguard their networks against unanticipated disruptions. Here’s how.
" "

Designing Resilience into Global Supply Chains

To address flaws exposed by the pandemic, companies should accelerate efforts to revamp their worldwide manufacturing and sourcing networks—even if that means extra cost.
Redrawing the Map of Global Trade

Redrawing the Map of Global Trade

Even when the global economy fully recovers, the international trade landscape will look dramatically different in the years ahead than it did before the pandemic.
health-care-operations-postpandemic-world-rectangle_tcm-252192.jpg

Health Care Operations in the Postpandemic World

Medtech and biopharma companies can rebound from the current crisis and prepare for an uncertain future.
how-an-eu-carbon-border-tax-could-jolt-world-trade-rectangle-tcm9-251990.jpg

How an EU Carbon Border Tax Could Jolt World Trade

Plans to tax CO2 emissions that are attributed to imports would hike costs for EU trade partners and redefine competitive advantage in many industries.
critical-priorities-pharma-medtech-response-covid-19-rectangle-tcm9-240805.jpg

Critical Priorities for Pharma and Medtech in Response to COVID-19

In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
responding-to-the-coronavirus-square-tcm9-241561.jpg

Responding to the Coronavirus’s Impact on Supply Chains

Understand the situation in your industry, consider multiple scenarios, and plot out both immediate actions and longer-term steps to lay the foundation for a strong recovery.
pharma-manufacturing-partnerships-more-strategic-2880x1620-tcm9-202064.jpg

Creating More Powerful Partnerships in Pharma Manufacturing

Companies are eager to shift more of the production they outsource to trusted strategic partners, but doing that right takes analysis and planning.
Deep Expertise, Broad Experience